Prescription oral antivirals taken at the first tingle are the most effective treatment for cold sores. A short course of valacyclovir or famciclovir can shorten an outbreak by roughly a day compared to doing nothing, and starting early sometimes prevents the sore from fully forming. But “best” depends on your situation: how often you get outbreaks, how quickly you can start treatment, and whether you have access to a prescription. Several over-the-counter options, combination creams, and even light-based devices also have clinical evidence behind them, and the differences between them are worth understanding.
Why Timing Matters More Than the Drug
Every cold sore treatment shares the same limitation: it works best when started during the prodrome, that tingling or burning sensation you feel before anything is visible. The herpes simplex virus reactivates in nerve tissue and travels to the skin surface, and once blisters have fully formed, the virus has already done most of its damage to skin cells. Antivirals can still reduce pain and speed healing at later stages, but the window for a dramatic difference is narrow. This is the single most important thing to know about cold sore treatment. A mediocre treatment started early will usually outperform a superior treatment started late.
Prescription Oral Antivirals
Valacyclovir (Valtrex) and famciclovir (Famvir) are the strongest options available and the closest thing to a consensus “best treatment.” Valacyclovir has been studied in a convenient one-day dosing regimen: two large doses taken 12 hours apart. In two multicenter trials, this single-day course reduced the median duration of a cold sore episode by a full day compared to placebo, and the mean duration dropped by about 1.1 days.1PubMed Central. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies That might not sound like much, but cold sore episodes typically last only four to five days in the first place, so shaving off a day is a meaningful proportion of the total misery.
Famciclovir works similarly and can also be taken as a single high-dose treatment. Both drugs are prodrugs of older antiviral compounds, designed to be absorbed better through the gut. Their advantage over topical creams is systemic delivery: the drug reaches the virus at the nerve level, not just at the skin surface. The practical upside is that you can keep a prescription on hand and take it the moment you feel the prodrome, without needing to locate and apply a cream five times a day.
Topical Antiviral Creams
Acyclovir 5% cream (prescription in some countries, over-the-counter in others) is the most widely available topical antiviral for cold sores. It works, but the effect is modest. In two randomized trials, acyclovir cream reduced the mean duration of a cold sore episode by roughly half a day compared to a vehicle cream, bringing the average episode down from about five days to about four and a half.2PubMed Central. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials Pain duration was also reduced. One useful finding from those same trials: the cream still showed benefit whether it was started early (during the prodrome) or late (at the papule or vesicle stage), though the effect was larger with earlier treatment.
Penciclovir 1% cream (Denavir) is a similar prescription topical that performs comparably in trials. Both creams need to be applied frequently, typically every two hours while awake, which can be inconvenient and easy to forget.
Over-the-Counter Docosanol
Docosanol 10% cream, sold as Abreva in the United States, is the only FDA-approved nonprescription antiviral for cold sores. Unlike acyclovir, which interferes with viral replication inside the cell, docosanol works by blocking the virus from fusing with cell membranes in the first place.3PubMed. The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process This different mechanism is the reason it is available without a prescription and the reason resistance is unlikely to develop.
In a large multicenter trial, docosanol reduced the median time to healing by about 18 hours compared to placebo. It also shortened the duration of pain and other symptoms like itching and tingling.4PubMed. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial The catch: treatment had to begin within 12 hours of symptom onset to show benefit.5PubMed. Docosanol: a topical antiviral for herpes labialis About 40% of docosanol-treated patients experienced an “aborted” episode, meaning the cold sore never fully developed, versus 34% in the placebo group. That gap was not statistically significant, which tells you that docosanol’s main benefit is speeding healing rather than preventing sores outright.
In practical terms, docosanol is a reasonable first-line option if you cannot get a prescription quickly. Its effect is smaller than oral valacyclovir, but it is available immediately at any pharmacy.
The Combination Cream Approach
One of the more interesting developments in cold sore treatment is the combination of 5% acyclovir with 1% hydrocortisone in a single cream, marketed as Xerese in the U.S. The idea is straightforward: the antiviral fights the virus while the steroid reduces inflammation and swelling. In clinical trials, this combination reduced the chance of a cold sore progressing to an ulcerative lesion and shortened healing time compared to either acyclovir alone or placebo.6PubMed. The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese™) in the treatment of recurrent herpes simplex labialis
A separate randomized trial using the same formulation (designated ME-609) found that 42% of treated patients avoided an ulcerative lesion entirely, compared to 35% using acyclovir cream alone and 26% using placebo.7PubMed. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial If your main goal is preventing the ugly blister stage, this combination cream has the best evidence for that specific outcome. It does require a prescription.
Hydrocolloid Patches
Cold sore patches, such as the Compeed Cold Sore Patch, are hydrocolloid bandages designed to cover the sore, keep it moist, and protect it from contamination. They do not contain an antiviral. In a randomized clinical study comparing the patch directly to acyclovir 5% cream, both treatments performed similarly: median healing time was about 7.5 days for the patch and 7.0 days for acyclovir cream, a difference that was not statistically significant.8PubMed. Randomized clinical study comparing Compeed cold sore patch to acyclovir cream 5% in the treatment of herpes simplex labialis
Patches are useful for a different reason than antivirals. They conceal the sore, which matters a lot to people who work face-to-face. They can be worn under makeup. And because they create a physical barrier, they reduce the risk of touching the sore and spreading the virus to your eyes or to another person. They are not a replacement for antivirals if speed of healing is the priority, but they are a legitimate part of the toolkit, especially combined with an oral antiviral taken at the prodrome stage.
Light and Laser Therapy
This is where the evidence gets genuinely surprising. Several small studies have tested low-level light therapy on cold sores, and the results have been more impressive than you might expect. A study comparing diode laser treatment to acyclovir cream found a mean recovery time of about 2.2 days in the laser group versus 3.4 days in the acyclovir group.9PubMed Central. Comparing the effect of diode laser against acyclovir cream for the treatment of herpes labialis A pilot study using a 1072-nm narrow-waveband light device found that a single five-minute treatment healed cold sores in about 4.3 days compared to 8.5 days with acyclovir cream applied five times daily.10Clinical and Experimental Dermatology. A pilot study of treatment of herpes labialis with 1072 nm narrow waveband light A follow-up randomized double-blind study with the same device showed a healing time of 6.3 days versus 9.4 days for a sham device.11Clinical and Experimental Dermatology. A randomised double‐blind study comparing the effect of 1072‐nm light against placebo for the treatment of herpes labialis
These numbers look dramatic, but the studies are small. The pilot study had only 31 participants, and even the double-blind follow-up was modest in size. No large multicenter trial has been done. Some consumer devices based on this concept are commercially available, but the evidence base is thin enough that dermatologists generally do not recommend them as a first-line treatment. If you already use oral antivirals and want something additional, light therapy is an interesting option, but do not ditch your valacyclovir prescription for a device you saw advertised online.
Lysine and Zinc
L-lysine is the most widely discussed dietary supplement for cold sores. The idea is that lysine competes with arginine, an amino acid that herpes simplex needs to replicate. The clinical evidence, though, is uneven. A review of the available studies concluded that lysine supplementation at doses under 1 gram per day appears ineffective for preventing or treating cold sores. At doses above 3 grams per day, patients reported feeling better about their symptoms, but the objective measures of benefit are less convincing.12PubMed Central. Lysine for Herpes Simplex Prophylaxis: A Review of the Evidence One older trial did find that lysine-treated patients had fewer infections per year and faster healing times.13Dermatologica. Success of L-Lysine Therapy in Frequently Recurrent Herpes simplex Infection: Treatment and Prophylaxis And in a survey-based study, 84% of respondents said lysine prevented recurrence or decreased frequency of outbreaks.14Journal of Antimicrobial Chemotherapy. Subjective response to lysine in the therapy of herpes simplex That is a subjective report, not a blinded trial, so take it accordingly.
Topical zinc oxide combined with glycine has shown a small but real benefit. In a randomized trial, patients who applied a zinc oxide/glycine cream within 24 hours of symptom onset healed in about five days compared to 6.5 days for placebo, with reduced severity of blistering, soreness, and itching.15PubMed. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine The effect size is similar to docosanol. Zinc oxide is cheap and widely available, making it a reasonable option if you prefer something non-pharmaceutical.
Knowing and Avoiding Your Triggers
Prevention is its own form of treatment. Cold sore triggers vary between people, but the most commonly reported ones are fatigue, colds or other illnesses, and sun exposure. A study looking at trigger patterns found that sun-induced flare-ups were reported by about 10% of the overall patient population, but that number jumped sharply in younger patients during summer months, reaching 40% among patients under 30 with recurrent infections diagnosed during July and August.16PubMed. Sunlight is an important causative factor of recurrent herpes simplex UV radiation can suppress local immune responses in the skin, giving the virus an easier path to the surface.
For people whose outbreaks are clearly sun-triggered, using a lip balm with SPF 30 or higher and reapplying it throughout the day is a simple measure that can reduce recurrence. Stress management, adequate sleep, and general immune support are harder to quantify in clinical terms but consistently show up in patient reports as factors that influence outbreak frequency.
Suppressive Therapy for Frequent Outbreaks
If you get cold sores more than about six times a year, your doctor may suggest daily suppressive antiviral therapy rather than treating each episode individually. A Cochrane systematic review found that a long-term daily regimen of valacyclovir resulted in fewer monthly outbreaks compared to taking valacyclovir only when symptoms appeared.17PubMed Central. Interventions for prevention of herpes simplex labialis The reduction was about 0.10 fewer episodes per month, which translates to roughly one fewer outbreak per year. That might sound modest on paper, but for someone who dreads each recurrence, it can meaningfully improve quality of life.
One thing worth knowing: even with suppressive therapy, breakthrough outbreaks still happen. Suppressive dosing reduces frequency and can reduce viral shedding, but it does not eliminate the virus from the nerve tissue where it hides. You should still keep episodic treatment on hand.
Cold Sores in Immunocompromised Patients
People with weakened immune systems, whether from chemotherapy, organ transplant medications, or conditions like HIV, face a different cold sore landscape. Outbreaks tend to be more severe, last longer, and occasionally become resistant to standard antivirals. In these patients, intravenous acyclovir has been the traditional treatment. A randomized study in immunocompromised patients found that IV acyclovir shortened the time to lesion healing, cessation of pain, and termination of viral shedding compared to placebo, and it was well tolerated.18PubMed. Acyclovir therapy for mucocutaneous herpes simplex infections in immunocompromised patients
The bigger concern for this population is antiviral resistance. Most resistance to drugs like acyclovir arises from mutations in the virus’s thymidine kinase gene, the same enzyme the drug depends on to become active.19PubMed Central. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections In healthy people, resistant strains are rare because the immune system handles them. In immunocompromised patients, resistant virus can cause persistent, painful lesions that do not respond to standard treatment. This is the patient group most urgently in need of new drug options.
New Drugs and the Possibility of a Cure
Pritelivir is the most promising new antiviral in development for herpes simplex. It works through a completely different mechanism than acyclovir and its relatives, targeting the virus’s helicase-primase complex rather than its DNA polymerase. Because the target is different, mutations that cause acyclovir resistance do not affect pritelivir’s effectiveness, and the same goes for foscarnet-resistant strains.20Journal of Medicinal Chemistry. Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections In a case series of immunocompromised patients with acyclovir-resistant infections, 19 out of 23 patients who received pritelivir experienced full resolution of their lesions within 28 days, and the drug was well tolerated.21PubMed Central. Pritelivir in Immunocompromised Patients with Mucocutaneous Acyclovir-Resistant Herpes Simplex Virus-Infections – First Case Series
Further out on the horizon, gene editing approaches are being explored to go after the latent virus itself, the reservoir hiding in nerve ganglia that makes herpes a lifelong infection. Researchers have used engineered meganucleases delivered by viral vectors to destroy latent HSV DNA in mice, eliminating 90% or more of latent virus in orofacial infection models and up to 97% in genital infection models.22Nature Communications. Gene editing for latent herpes simplex virus infection reduces viral load and shedding in vivo This work is still in animal models and years from clinical use, but it represents the only strategy that aims to cure herpes rather than suppress it. If gene editing eventually reaches human trials with similar efficacy, it would be a genuine transformation in how we think about herpes simplex infections.
Does Treating a Cold Sore Prevent Spreading It?
A common hope is that taking antivirals will protect the people around you. The reality is more nuanced. The virus sheds from skin during both symptomatic and asymptomatic periods, and treatment with topical antivirals has a limited effect on overall transmission at the population level. A mathematical modeling study predicted that even a substantial increase in topical antiviral use would reduce the overall prevalence of infectious HSV-1 by no more than about 5%.23PubMed Central. Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and on antiviral resistance: predictions of mathematical models Oral antivirals do reduce shedding more than topicals, but you should still avoid kissing and sharing utensils or towels during an active outbreak, regardless of what treatment you are taking.
The virus also poses a specific risk to newborns and to people with eczema, in whom it can cause widespread skin infection. During an active sore, basic hygiene matters more than any drug for protecting vulnerable people around you: wash your hands frequently, do not touch the sore and then touch someone else, and avoid close contact with infants.24Journal of Antimicrobial Chemotherapy. The many challenges of facial herpes simplex virus infection